In June 2024, Novo Nordisk and Eli Lilly dominated the obesity market, with Novo Nordisk generating $6.3 billion and Eli Lilly $2.3 billion in sales from their weight-loss drugs in Q1 2024
Brain Health and Neuroprotection Kumar describes a patient with a strong family history of Alzheimers who asked to try a GLP-1 for dementia prevention
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
No, Semorelin, Ipamorelin-CJC1295 or other true growth hormone stimulating injectables are only available via a prescription
"I'm on GLP-1s and I'm barely hungry
MedicalDaily Evidence Check The evidence base for BPC-157, TB-500, and MOTS-C consists of animal studies, small pilot human trials, and anecdotal clinical reports, none of which meet the standard of a Phase 3 randomized controlled trial required for FDA drug approval